NCT02603887 2026-01-29Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple MyelomaM.D. Anderson Cancer CenterPhase EARLY_PHASE1 Active not recruiting20 enrolled 12 charts